Islandija -
islandščina -
LYFJASTOFNUN (Icelandic Medicines Agency)
taptiqom sine (taptiqom) augndropar, lausn 15 microg/ml + 5 mg/ml
santen oy* - tafluprostum inn; timololum maleat - augndropar, lausn - 15 microg/ml + 5 mg/ml
Islandija -
islandščina -
LYFJASTOFNUN (Icelandic Medicines Agency)
dasatinib krka filmuhúðuð tafla 70 mg
krka d.d. novo mesto* - dasatinibum inn - filmuhúðuð tafla - 70 mg
Islandija -
islandščina -
LYFJASTOFNUN (Icelandic Medicines Agency)
efexor depot hart forðahylki 150 mg
upjohn eesv - venlafaxinum hýdróklóríð - hart forðahylki - 150 mg
Islandija -
islandščina -
LYFJASTOFNUN (Icelandic Medicines Agency)
efexor depot hart forðahylki 75 mg
upjohn eesv - venlafaxinum hýdróklóríð - hart forðahylki - 75 mg
Islandija -
islandščina -
LYFJASTOFNUN (Icelandic Medicines Agency)
terbinafin medical valley tafla 250 mg
medical valley invest ab - terbinafinum hýdróklóríð - tafla - 250 mg
Islandija -
islandščina -
LYFJASTOFNUN (Icelandic Medicines Agency)
venlafaxin medical valley forðatafla 225 mg
medical valley invest ab - venlafaxinum hýdróklóríð - forðatafla - 225 mg
Islandija -
islandščina -
LYFJASTOFNUN (Icelandic Medicines Agency)
pedippi mixtúruduft, dreifa 2 mg/ml
oresund pharma aps - omeprazolum inn - mixtúruduft, dreifa - 2 mg/ml
Evropska unija -
islandščina -
EMA (European Medicines Agency)
ebglyss
almirall, s.a. - lebrikizumab - dermatitis, atópísk - aðrar húðsjúkdómar - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.
Islandija -
islandščina -
LYFJASTOFNUN (Icelandic Medicines Agency)
vancomycin-mip innrennslisstofn, lausn 1000 mg
mip pharma gmbh - vancomycin hydrochloride - innrennslisstofn, lausn - 1000 mg
Islandija -
islandščina -
LYFJASTOFNUN (Icelandic Medicines Agency)
vancomycin-mip innrennslisstofn, lausn 500 mg
mip pharma gmbh - vancomycin hydrochloride - innrennslisstofn, lausn - 500 mg